HOLLAND, OH--(Marketwire - January 05, 2009) - Wellstar International, Inc. (OTCBB: WLSI), a
provider of specialized diagnostic software and equipment, announced today
that its wholly-owned subsidiary, Trillennium Medical Imaging ("TMI"), is
ready to begin marketing its thermal imaging system to long-term care
("LTC") facilities in the United States. National statistics currently show
that the incidence rate of pressure ulcers, commonly known as bed sores, is
up to 28% of the population for those living in LTC facilities; with many
leading experts believing the rate is even higher.
LTC facilities generally care for patients that are critically and/or
terminally ill, bed-ridden, and that show higher rates of dementia; all
indicators that put an individual at risk for developing a pressure ulcer.
TMI's thermal imaging diagnostic device will equip care personnel at these
facilities with the ability to objectively identify patterns of injury
associated with the development of pressure ulcers. This kind of early
detection can lead to intervention and even prevention. By identifying the
tissue changes associated with the development of these wounds prior to
skin breakdown, a patient can receive considerably better care by avoiding
pressure ulcer occurrence altogether. When long-term care facilities can
reduce the occurrence of pressure ulcers, they receive a higher rating in
the pay for performance ("P4P") initiative from the Centers for Medicare &
Medicaid Services ("CMS").
Utilizing TMI's thermal imaging system technology will enable an LTC
facility to provide better overall patient care and significantly lower its
pressure ulcer incidence rate. By having complete documentation of every
skin assessment performed, an LTC facility can mostly curtail its
liabilities by protecting itself against costly lawsuits.
With nearly 16,000 long-term care facilities in the United States, and an
aging population that is increasing in numbers year after year, TMI has an
enormous and largely untouched market to go after with its revolutionary
system. TMI's marketing plan includes a program where LTC facilities can
lease the equipment necessary to perform skin assessments and store the
necessary data. Lease plans start at a minimal monthly fee of $2,000 per
unit. This monthly fee allows for unlimited imaging, a factor that should
help promote aggressive imaging/assessment programs by these facilities.
Wellstar/TMI CEO, John Antonio, commented: "We have already seen a positive
response to our thermal imaging system among the LTC facilities we have
been engaged with. We expect significant revenue potential within the LTC
market, and the Company anticipates placing initial units within these
facilities sometime within the first quarter of 2009."
The company has developed its thermal imaging system for various
applications. The TMI technology and software has been approved by the FDA
as an Adjunctive Diagnostic Screening Procedure for early breast cancer
detection, differential diagnoses of pain dysfunctions (such as Reflex
Sympathetic Dystrophy, Neuromuscular Skeletal Syndromes and neurological
disorders), for the early detection of pressure ulcers, deep tissue
injuries, and bedsores, as well as for orthopedic applications. The company
has plans to market diagnostic systems for all of the above mentioned
applications.
ABOUT WELLSTAR INTERNATIONAL, INC.:
Wellstar International, Inc., through its wholly owned operating subsidiary
Trillennium Medical Imaging, Inc. (TMI), is poised to become a leading
diagnostic company in the health care industry. TMI has developed and is
marketing fully calibrated and functional, thermal imaging systems that
utilize state-of-the-art infrared technologies and proprietary software to
accurately and cost-effectively measure physiological changes in the human
body. More information on the Company and its unique diagnostic software
and product line is available on Wellstar's corporate Website, by visiting:
www.wellstar.us.
FORWARD-LOOKING STATEMENTS:
This press release contains statements, which may constitute
'forward-looking statements' within the meaning of the Securities Act of
1933 and the Securities Exchange Act of 1934, as amended by the Private
Securities Litigation Reform Act of 1995. Prospective investors are
cautioned that any such forward-looking statements are not guarantees of
future performance and involve risks and uncertainties, and that actual
results may differ materially from those contemplated by such
forward-looking statements. Important factors currently known to management
that could cause actual results to differ materially from those in
forward-statements include fluctuation of operating results, the ability to
compete successfully and the ability to complete before-mentioned
transactions. The company undertakes no obligation to update or revise
forward-looking statements to reflect changed assumptions, the occurrence
of unanticipated events or changes to future operating results.
